Abstract:<h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Background</h3><p><strong>:</strong> Therapeutic regimens of breast cancer treatment are increasingly inclined to adopt combination strategy based on the broad spectrum antitumor effect of doxorubicin (Dox). Currently, combination therapy comprises of conventional anti-cancer drugs and angiogenesis inhibitors have been corroborated as an effective approach in cancer treatment.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Purpose</h3><p><strong>:</strong> We explored the ability of a natural anti-angiogenic compound glycyrrhetinic acid (GA), derived from an edible-medicinal herb licorice, to enhance the breast cancer suppression effect of Dox.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Study Design</h3><p><strong>:</strong> The drug ratio of GA and Dox with synergistic anticancer effect against MCF-7 cells was optimized by combination index (CI) value <em>in vitro</em>, followed by evaluation of the improved anticancer effects and reduced side-effects of this combination <em>in vitro</em> and <em>in vivo</em>.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Methods</h3><p><strong>:</strong> Cell viability was measured by MTT assay. Analyses of mitochondrial membrane potential and cell apoptosis on MCF-7 cells were performed by JC-1 dye and Annexin V-FITC/PI assays. The cellular accumulation of Dox when combined with GA was evaluated. Levels of apoptosis-related proteins in MCF-7 cells were measured by Western blot analysis. Synergistic anti-angiogenic effects on HUVECs were evaluated. A breast cancer mouse model was established to investigate the anti-tumor effects <em>in vivo</em>.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Results</h3><p><strong>:</strong> Based on the optimization by CI value, Dox and GA at 1:20 molar ratio was chosen as the optimal combination drug ratio that exhibited synergistic effect against MCF-7 breast cancer cells. In addition, the combination of GA and Dox exhibited significantly enhanced cytotoxicity, apoptosis, and loss of mitochondrial membrane potential <em>via</em> the upregulation of a mitochondrial-dependent apoptosis pathway against MCF-7 cells. Interestingly, the addition of GA increased the intracellular accumulation of Dox in MCF-7 cells. Moreover, VEGF-induced HUVECs proliferation, migration, and tube formation were strongly inhibited by Dox when used with GA via the significant down-regulation of VEGFR2-mediated pathway, indicating that the combination of Dox and GA could exhibit ideal synergistic anti-angiogenesis effect. Expectedly, the enhanced anti-tumor efficacy of Dox and reduced Dox-induced cardiotoxicity when used in combination with GA were evident in a mouse breast tumor model.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Conclusions</h3><p><strong>:</strong> These findings support that the combination of Dox with GA is a novel and promising therapeutic strategy for the treatment of breast cancer.</p>

Note on the form of the metric for an isolated vortex in general relativity.

Synergistic effects of antitumor efficacy <i>via</i> mixed nano-size micelles of multifunctional <i>Bletilla striata</i> polysaccharide-based copolymer and D--tocopheryl polyethylene glycol succinate

[Hepatitis B virus infection in children born to mothers with acute hepatitis B].

Co-Encapsulation of Simvastatin and Doxorubicin into pH-Sensitive Liposomes Enhances Antitumoral Activity in Breast Cancer Cell Lines

Hybrid Nanosystem Formed by DOX-Loaded Liposomes and Extracellular Vesicles from MDA-MB-231 Is Effective against Breast Cancer Cells with Different Molecular Profiles

2‐Deoxy‐2‐fluoro‐D‐galactose protein N‐glycosylation

Preparation, Characterization and Evaluation of Liposomal Doxorubicin and Harmine That Show Synergistic Activity in Vitro

Co-delivery of doxorubicin, docosahexaenoic acid, and α-tocopherol succinate by nanostructured lipid carriers has a synergistic effect to enhance antitumor activity and reduce toxicity

Ph-Responsive Polymeric Micelles Based on Poly(2-Ethyl-2-oxazoline)-poly(d,l-lactide) for Tumor-Targeting and Controlled Delivery of Doxorubicin and P-glycoprotein Inhibitor

pH-sensitive doxorubicin-tocopherol succinate prodrug encapsulated in docosahexaenoic acid-based nanostructured lipid carriers: An effective strategy to improve pharmacokinetics and reduce toxic effects

Multifunctional drug-loaded micelles encapsulated in thermo-sensitive hydrogel for in vivo local cancer treatment: Synergistic effects of anti-vascular and immuno-chemotherapy

Combination of Doxorubicin with Harmine-Loaded Liposomes Exerting Synergistic Antitumor Efficacy.

Glucose and Triphenylphosphonium Co-Modified Redox-Sensitive Liposomes to Synergistically Treat Glioma with Doxorubicin and Lonidamine

Synergistic breast cancer suppression efficacy of doxorubicin by combination with glycyrrhetinic acid as an angiogenesis inhibitor

CD44/Folate Dual Targeting Receptor Reductive Response PLGA-Based Micelles for Cancer Therapy

Decreased BOLD responses in audiovisual processing

Coadministration of Glycolipid-Like Micelles Loading Cytotoxic Drug with Different Action Site for Efficient Cancer Chemotherapy

Co-delivery of Doxorubicin and Curcumin with Polypeptide Nanocarrier for Synergistic Lymphoma Therapy

Liposomes as multicompartmental carriers for multidrug delivery in anticancer chemotherapy

Sacral nerve neuromodulation in patients with underlying neurologic disease.

Glycyrrhetinic acid remodels the tumor microenvironment and synergizes with doxorubicin for breast cancer treatment in a murine model